The quality of life index: a pilot study integrating treatment efficacy and quality of life in oncology.
Amrita BasuE J PhilipBarry D DewittJ HanmerA ChattopadhyayC YauM E MeliskoLaura J EssermanPublished in: NPJ breast cancer (2020)
The majority of women diagnosed with breast cancer will experience some form of drug-related toxicity and subsequent impairments in Health-related Quality of Life (HRQoL). Despite this, HRQoL is assessed inconsistently and there is no validated method to integrate HRQoL data into the assessment of therapeutic agents. This proof of concept study utilizes data from the neoadjuvant I-SPY 2 clinical trial to describe the development of the Quality of Life Index (QoLI) measure. The QoLI represents a single composite score that incorporates validated longitudinal measures of clinical efficacy and QoL and one that permits a more comprehensive, direct comparison of individual therapeutic agents. Preliminary data suggest the QoLI is able to distinguish between agents based on their efficacy and toxicity; with further validation, the QoLI has the potential to provide more patient-centered evaluations in clinical trials and help guide treatment decision making in breast cancer and other oncologic diseases.
Keyphrases
- clinical trial
- electronic health record
- big data
- rectal cancer
- squamous cell carcinoma
- phase ii
- type diabetes
- prostate cancer
- palliative care
- machine learning
- metabolic syndrome
- adipose tissue
- breast cancer risk
- combination therapy
- climate change
- locally advanced
- risk assessment
- randomized controlled trial
- study protocol
- double blind
- insulin resistance
- radical prostatectomy
- minimally invasive
- phase iii